August 11, 2021 7:46am

The Biostage (BSTG) Chronicles: A quote from their website, “Biostage has built a dedicated internal team of FOUR (4) materials scientists, engineers and biologists who are LEFT working with our external collaborators (NONE) to bring our product to the patients who need them as quickly as possible.” The approved IND is 1 year and 5 months old, WHY is there NO clinical trial initiation.” <read more questions left unanswered>

Pre-open indications: 1 BUY; 3 SELLs: 2 SELLs into Strength; 1 Maintain SELL

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

There is no breadline for fact and numbers-based share pricing intelligence!


Dow futures are UP +0.02% (+6 points), S&P futures are DOWN -0.11% (-5 point) and NASDAQ futures are DOWN -0.21% (-31 points)

 

U.S. stock index futures on Wednesday are mixed and fluctuating pointing to a soft open ahead of the inflation release (CPI) that could determine how fast the Fed moves to limit monetary stimulus,

European markets reacted cautiously and were mixed as global markets nursing Covid-19 developments and key economic data.

Asia-Pacific markets were also mixed with modest gains.

 

Data Docket: Consumer Price Index (CPI)

 

Henry’omics:

If the CPI report comes in even hotter than expected, stocks could take a hit on fears it may cause the Fed to taper its monthly $120 billion bond purchases on a faster schedule than the market is prepared for, setting the table for an eventual rate increase. <CNBC>

The Nasdaq slid -72.09 points or -0.49%, registering its second (2nd) negative session in the last three (3).

Be ready for TROUBLE in markets, the Senate passed the infrastructure bill yesterday, Tuesday which earmarks $550 billion in new spending for areas including transportation and the electric grid.

 

Tuesday’s evening’s recap: “earnings’ season is not for the faint-of-heart sector investor. What’s missing, the positivity within the sector!”https://www.regmedinvestors.com/articles/12042

  • The Nasdaq closed DOWN -72.09 points (-0.49%);
  • The IBB closed down -1.81% and XBI closed down -0.82%
  • Sector volume INCREASED with 6 of the 12-upside having higher than the 3-month average volume with very LOW volume of 4 of 21-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.07 points or +0.42% at 16.79;
  • Tuesday’s percentage (%) of the 12-upside were +0.03% (QURE) to +10.35% (BLUE) while the 21-downside -0.33% (MDXG) to -11.91% (AXGN);

Q3/21:

  • August: 4 positive and 3 negative closes
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • BioLife Solutions (BLFS) – today;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?

Biostage (BSTG) closed flat Tuesday with 4 shares traded after Monday’s down -$0.05 with 1060 shares traded, Friday’s +$0.05 on Friday with 709 shares traded, Thursday with 5 shares traded and last Wednesday with 50 shares traded.

Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?

Question#2: On July 9th an 8-K was issued saying “Wei & Wei and Co” was engaged. Are they registered in Massachusetts, not according to their website after RSM US LLP walked – i.e., “ceased their engagement”? So, when, is their quarterly earnings being released?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

Pre-open Indications: the dice get rolled in this frenetic market and resulting sector bumps and dumps

SELL into Strength:

Editas Medicine (EDIT) with a negative -$0.24 pre-open indication, Intellia Therapeutics (NTLA) with a negative -$0.86 pre-open indication

 

SELL:

CRISPR Therapeutics (CRSP) with a negative -$2.74 pre-open indication, bluebird bio (BLUE) with a negative -$0.34 pre-open indication, Voyager therapeutics (VYFR) with a negative -$0.11 pre-open indication

 

BUY:

Sage Therapeutics (SAGE) with a positive +$0.52% pre-open indication

 

The BOTTOM LINE: the recent bout of pricing inconsistency in the cell and gene therapy sector could be chalked up to LACK of any … impression in my 35 covered companies in this Q2 earnings season,

I was skittish over Friday and NERVOUS as Monday while Tuesday didn’t seem to be taking shape and Wednesday will be dependent on macro-economic numbers – re direction.  

The cell and gene therapy sector has experience dramatic upside move and downside putting a real edge on share pricing as earnings continued to guide sector sentiment … following last week’s twenty-one (21) releases to date – hey, one (1) today.

Q2 earnings potential LPS (loss-per-share): coming “attractions”

  • BioLife Solutions (BLFS) – 8/12

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC), Bellicum Pharmaceuticals (BLCM), Biostage (BSTG), Homology medicine (FIXX), Mesoblast (MESO), Pluristem (PSTI) and Solid Biosciences (SLDB)

Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.

Risk is no doubt increasing as we head into the troublesome August and September months

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.